EGFR and neoplasm: Gefitinib is alow-molecular-weight competitive inhibitor of ATP-binding pocket of the EGFR TKdomain [11], which is approved for the treatment of nonsmall cell lung cancer.Clinical trials of gefitinib as a single agent in CRC reported no objective tumor responses [12–14] however, a sizable proportion ofpatients did have disease stabilization.